CN1546683A - Aspartic transaminase mitochondrion isozyme m type measurement method - Google Patents
Aspartic transaminase mitochondrion isozyme m type measurement method Download PDFInfo
- Publication number
- CN1546683A CN1546683A CNA2003101094243A CN200310109424A CN1546683A CN 1546683 A CN1546683 A CN 1546683A CN A2003101094243 A CNA2003101094243 A CN A2003101094243A CN 200310109424 A CN200310109424 A CN 200310109424A CN 1546683 A CN1546683 A CN 1546683A
- Authority
- CN
- China
- Prior art keywords
- asts
- serum
- reagent
- astm
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the Aspartic transaminase mitochondrion isozyme m type (ASTm) measurement method which includes, employing immunodepression and specific bonding of sheep anti-Human ASTs antibody with ASTs in serum, inhibiting ASTs to non-reactive and ASTm residue in serum, employing enzyme kinetic method to determine ASTm type reactivity (U/L), diagnosis of cytoclasis amount in myocardiac infarction and liver diseases as the evaluation index for judgement and forecast.
Description
Technical field:
The present invention relates to biological technical field, be specifically related to aspartic acid based transferase Mitochondria Isoenzyme m type (ASTm) measuring method.
Technical background:
(Aspartate aminosferase, AST) or claim glutamic-oxal(o)acetic transaminase (GOT) that two kinds of isozymes are arranged, a kind of is the ASTs type to the serum aspartic transaminase, is mainly derived from cytoplasm.A kind of is the ASTm type, is present in the cell mitochondrial.These two kinds of isozymes extensively are present in the organs and tissues such as the heart, liver, skeletal muscle, kidney, are up to 60-80% with content in heart and the hepatic tissue especially, and these visceral organ injuries can make that isozyme increases in the serum.The degree difference of damage, the ratio of two kinds of isozymes in serum are also different.
When internal organs such as liver or heart suffer damage, the gross activity (including ASTs type and ASTm type) that AST in the serum is measured in Clinical Laboratory now raises, the ASTs type is present in the cytoplasm, mainly be that inflammation makes the cell permeability changes and discharges into blood system, be the index of a reflection inflammation, cell is not downright bad in this case.And the ASTm type generally will be in necrocytosis, after plastosome destroys in the kytoplasm, just is released into blood.Therefore, the degree of necrosis of ASTm offset reflection cell, its ASTm is active relevant with the size of necrosis region.Two kinds of isozyme transformation period in serum are also different, and ASTm type elimination factor in blood is faster more than 5 times than ASTs type.When cell no longer destroyed and repairs, the ASTm value was reduced to normal level very soon in the blood.Therefore, ASTm is again the index of prognostic evaluation.
If measure the gross activity of AST, include two types of ASTs and ASTm clinically.Can not dividing the patient is struvite change, or necrocytosis.As myocardial infarction to diagnose myocardium cell necrosis degree, necrotic lesion what, judge treatment and prognosis.Gross activity raises and to comprise 70% struvite ASTs and can't judge or false judgment.
The active rising of CKMB myohaemoglobin and Troponin I or TnT is mainly measured in the detection of myocardial infarction disease clinically, can judge myocardial infarction at short notice, but it is not high to have crossed 24 hours diagnostic values.And ASTm measures, and mainly surveys its necrocytosis degree.Damage is more serious, and the ASTm value is higher in the serum.As the damage do not continue to increase the weight of, because of ASTm transformation period in serum very short, reduce to normal value rapidly, the prognosis bona.After thromboembolism treatment and other medicines treatment, reduce as the necrocytosis degree, the active decline of ASTm then illustrates the prognosis bona.
After the Acute Myocardial Infarction, the appearance that ASTm raises in serum is than creatine kinase, myohaemoglobin evening.In the myocardial anoxia stage, the permeability of cytolemma changes, and ASTs at first is released into serum, when myocardium cell necrosis appears then showing in ASTm in blood.By result of treatment that dynamic observes the decidable myocardial infarction and prognosis situation to ASTm.
The ASTm activity change is mainly measured in the adult and the differential diagnosis of children's's myocarditis, AST gross activity rising during inflammation, and ASTm do not raise (cell does not have necrosis).
In recent years, the mensuration that has been fully recognized that ASTm is clinically judged significant to the diagnosis of hepatopathy and Acute Myocardial Infarction and prognosis, to commonly used at present the having of measuring method of ASTm:
(1) electrophoretic method, this method is simpler, but can only qualitative and sxemiquantitative, and sensitivity is low;
(2) ion-exchange chromatography method, this method effort again consuming time, and also certain serum giant molecule that combines with ASTs may be washed during wash-out ASTm, cause error;
(3) immuno-precipitation, the last two kinds of methods of this method come easyly, accurate, but must in the laboratory of special use, carry out, can't realize in time detecting fast clinically.
Summary of the invention:
Technical problem to be solved by this invention is to adopt immunodepression, and a kind of method that quick and precisely detects the ASTm type is provided, the reference frame of judging as clinical judgment cardiac muscle or hepatocellular damage degree and curative effect assessment, prognosis.
The reagent that employing immunodepression disclosed by the invention is measured the method employing of ASTm comprises reagent I: the tris buffer, potassium aspartate, serum lactic dehydrogenase, goat-anti people ASTs antiserum(antisera), the sodium alpha-ketoglutarate that contain pH8.0 ± 0.2; With reagent II: contain pH8.0 ± 0.2 tris buffer, sodium alpha-ketoglutarate, DPNH.
ASTm measuring method of the present invention specifically comprises: add reagent I in blood sample to be measured, goat-anti people ASTs antibody among the reagent I is combined with ASTs specificity in the serum, inhibition ASTs is a non-activity, remaining in the serum is ASTm, adopt the enzyme kinetics method to measure ASTm type activity (U/L), the necrocytosis amount how much in diagnosing cardiac infarction and the hepatic diseases, as judging and prediction evaluating prognosis index.
The basic location parameter of ASTm measuring method of the present invention is:
Get reagent I, add in the quality-control sample, put 37 ℃ of water-baths and add reagent II after 5 minutes, put 37 ℃ of water-baths after 1 minute, on spectrophotometer, measure 3 minutes absorbancy changing values with wavelength 340nm, divided by 3, calculate the absorbancy changing value Δ A/min of average per minute, press ASTm (U/L)=Δ A/min * F calculation result, wherein F is a constant-3225.
Goat-anti people ASTs antibody described in the reagent I of the present invention is made by following method:
Human heart takes out in after death 24 hours, is divided into about 100g, preserves-80 ℃ of conditions and preserves stand-by.
1, the thick extraction:
Treat the tundra material, add the damping fluid that contains the pyridoxal phosphate protein stabiliser, destroy cell with the cell pulverization machine and make homogenate, the low temperature ultracentrifugation, get supernatant liquor and be heated to 50 ℃-55 ℃, the low temperature ultracentrifugation is removed the sex change foreign protein again, obtains crude extract homogenate through 50% and 33% secondary saturated ammonium sulphate, and (operating) dialysed, concentrated to homogenate with water-soluble Jie of distillation under 4 ℃ of conditions.
2, chromatographic separation:
With affinity column and ion exchange column on the thick concentrated solution, collect the ASTs elutriant, by the time the ASTs antigen of purifying.Measure the purity of purifying product then and (identify with cellulose acetate electrophoresis and separate that the electrophoresis position is at α
2The sphaeroprotein position), enzyme activity determination (use clinical biology, the biochemical method that IFCC recommends is measured the AST activity).
3, immune animal:
Get healthy, the heavily adult bright and beautiful sheep of male about 50kg, carry out immunity.For the first time add bacille Calmette-Guerin vaccine and Fu Dai adjuvant mixing with antigen, inject bright and beautiful sheep neck lymph and muscle tissue, per 2 weeks, once immunity was 4 times-5 times altogether, and the antigen amount increases and decreases according to the weight of animals.The two weeks back blood sampling that immunity is last.Serum obtains goat-anti people ASTs antiserum(antisera) through purifying (handling with 50% ammonium sulfate saturated solution), and mensuration is tired, and is standby.
Goat-anti people ASTs antibody of the present invention is suitable for serum or blood plasma (no haemolysis) sample standard deviation inhibiting rate 〉=75% of ASTs.
For estimating aspartic transaminase isozyme of the present invention (ASTs) antibody to the active inhibition ability of serum ASTs, the spy has carried out relevant inhibition capability evaluation test:
One, antibody is to the active inhibition ability of ASTs
Get the ASTs that from people's liver cell endochylema, purifies and add in the SA serum specimen, suppress this ASTs sample respectively, observe of the influence of ASTs antibody concentration inhibiting rate with the different ASTs antibody of measuring.Step and the results are shown in Table 1.
Table 1 antibody is to the inhibition ability of ASTs
Anti-body contg (μ l) 05 10 15 20 25 30 35
ASIs sample (μ l) 35 35 35 35 35 35 35 35
37℃5min
Residue AST activity (U/L) 346 84.2 42.6 43.4 43.3 42.9 45.1 44.1
Inhibiting rate (%) 75.7 87.7 87.5 87.5 87.6 87.0 87.3
Interpretation of result: 5 μ l antibody amounts still are not enough to reach its due inhibition ability, and inhibiting rate tends towards stability after the 10 μ l, can think about 88% activity among this ASTs antibody capable inhibition ASTs like this.
Two, antibody is to the inhibition ability of ASTs in the serum
Get a high AST active serum, the ASTs antibody with different amounts suppresses serum specimen respectively, observes the influence of ASTs antibody concentration to inhibiting rate.Step and the results are shown in Table 2.
Table 2 antibody is to the inhibition ability of ASTs in the serum
Anti-body contg (μ l) 05 10 15 20 25 30 35
Serum specimen (μ l) 35 35 35 35 35 35 35 35
37℃5min
Residue AST activity (U/L) 883 384 241 237 228 230 231 227
Inhibiting rate (%) 56.5 72.7 73.2 74.2 74.0 73.8 74.3
Interpretation of result: contain ASTm in this serum sample.Under this experiment condition, can suppress most ASTs with this ASTs antibody 10 μ l are above, and the AST gross activity be reached the serum specimen that 900U/L, ASTs reach about 800U/L the inhibition ability is also arranged.
Three, antibody suppresses the intersection of ASTm
Separate observation serum sample AST isozyme distribution situation with cellulose acetate electrophoresis.Get three parts of AST activity and be respectively 883,563, the serum of 241U/L carries out electrophoretic analysis after suppressing with 10 μ l antibody respectively, observes the variation of AST isozyme collection of illustrative plates before and after suppressing.
Interpretation of result: all visible ASTs of three parts of serum AST isozyme electrophoresis and ASTm district band, and the dyeing depth is proportionate with gross activity, ASTs district band dyes darker, the ASTm district be with dye more shallow.After suppressing, the also visible ASTs antibody of electrophoresis is to ASTm district band, and ASTm district band dye levels is to similar without what suppress, and the band dyeing of ASTs district shoals.The result shows that this ASTs antibody does not have the inhibition of intersection substantially to ASTm, can suppress most ASTs activity.
Conclusion: this ASTs antibody and serum sample ratio are between 1: 3.5～1: 1, and 37 ℃ of 5min can suppress about 88% ASTs, ASTm is not had to intersect substantially suppress.
The detection kit of using reagent of the present invention to form is measured the ASTm in human serum or the blood plasma external, through on-line analysis, can obtain measurement result about five minutes, has realized the timely detection of ASTm.
Description of drawings:
Fig. 1 embodiment 3 serum dilution test ASTm linearity curves
Fig. 2 embodiment 3 reaction process curves
Embodiment:
Embodiment 1 ASTm detection kit
1, reagent:
Reagent I:
Tris buffer pH8.0 ± 0.2 1.2g
Potassium aspartate 2.72mg
Serum lactic dehydrogenase 0.32mg
Malate dehydrogenase (malic acid dehydrogenase) 0.12mg
Goat-anti people AST antiserum(antisera) 0.96ml
Sodium alpha-ketoglutarate 0.24g
Pure water 80ml
Reagent II:
Pehanorm pH of buffer 8.0 ± 0.2 0.0784g
Sodium alpha-ketoglutarate 0.06g
DPNH 0.0224g
Pure water 20ml
2, instrument:
Hitachi's 7150 (7170) type automatic clinical chemistry analyzers.
3, analytical procedure
Immunodepression and enzyme kinetics method.
4, sample requirement
Serum or blood plasma (no haemolysis) are measured after the blood sampling as early as possible.
5, technical requirements
Working conditions:
Use temperature: 37 ℃;
Use wavelength: 340nm
5.1 goat-anti is stopped ASTs serum performance index
ASTs antibody is to the inhibiting rate of ASTs: 〉=75%
5.2 reagent blank absorbance: 1.00A≤reagent I+ reagent II≤1.600A
(340nm, cuvette optical path 1cm)
5.3 measurement range: 5U/L-130U/L relation conefficient γ 〉=0.995
5.4 sensitivity: 5 ± 2 (U/L)
5.5 stability:
Store 24h blank absorbency value at 35 ℃ and answer 〉=1.30A, 48h 〉=1.20A, during 72h 〉=1.00A (340nm, cuvette optical path 1cm).
5.6 repeated CV≤5% (level
115U/L, level
2130U/L, n=20).
5.7 reagent outward appearance
Should be achromaticity and clarification liquid.
6, test method
6.1 goat-anti people ASTs antiserum(antisera) performance test
Add in the active serum of known high AST 6.1.1 get a certain amount of ASTs antibody, measure the active inhibiting rate that calculates ASTs of residual A STm behind 37 ℃ of incubation 5min, its result should meet 5.1 requirements.
6.2 reagent blank absorbance test
Get reagent I 1.6ml, add pure water 0.12ml, put 37 ℃ of water-baths and add reagent II0.4ml after 5 minutes, put 37 ℃ of water-baths after 1 minute, on 722 spectrophotometers, measure absorbance, should meet 5.2 requirements with the 340nm wavelength.
6.3 useful range test
Get 5U/L, 15U/L, 30U/L, 65U/L, five kinds of concentration quality-control samples of 130U/L repeat three times as follows and measure, and get average.
Get reagent I1.6ml reagent, add quality-control sample 0.2ml, put 37 ℃ of water-baths and add reagent II0.4ml after 5 minutes, put 37 ℃ of water-baths after 1 minute, on 722 spectrophotometers, measure 3 minutes absorbancy changing values with wavelength 340mm wavelength, divided by 3, promptly use Δ A/min calculation result, should meet 5.3 requirements, promptly in 5-130U/L, be linear.
6.4 sensitivity test
Get reagent I1.6ml, add 5U/L quality-control sample 0.12ml, put 37 ℃ of water-baths and add reagent II0.4ml after 5 minutes, put 37 ℃ of water-baths after 1 minute, on 722 spectrophotometers, measure 3 minutes absorbancy changing values with wavelength 340nm wavelength, divided by 3, the gained result should meet 5.4 requirements.
6.5 stability
Test kit was placed on 35 ℃ of storages after 24,48,72 hours, measures the blank absorbency values, should meet 5.5 requirements by 6.2 described methods.
6.6 replica test
Test with 15U/L and two quality control products of 130U/L.
Respectively 15U/L and two quality control products of 130U/L are carried out heavy mensuration 20 times by 5.4 described methods, obtain per minute absorbancy change mean X and standard deviation S, be calculated as follows the CV value, should meet 5.6 and require:
Embodiment 2,
Use instrument: HITACHI 7060C; Temperature: 37 ℃; Wavelength: 340nm (predominant wavelength), 405nm (commplementary wave length); Sample size: 20 μ l, damping fluid: reagent I (with embodiment 1) 240 μ l mixings, hatched five minutes for 37 ℃, add enzyme liquid reagent II (with embodiment 1) 60 μ l mixings then, 37 ℃ hatch one minute after, survey A1=1.3285,37 ℃ hatch three minutes after, survey A
2=1.3111, calculate absorbancy changing value (the Δ A/ branch)=(A of average per minute
2-A
1)/3=(1.3111-1.3285)/3=-0.0058, calculation result: m-AST (U/L)=Δ A/min * F, F=-3225, Δ A/min=-0.0058
m-AST(U/L)＝-0.0058×(-3225)＝19(U/L)。
Embodiment 3 ASTm detection method linearities of the present invention, reaction process, precision, the rate of recovery and interference test
One, serum dilution test
Getting a serum AST-m is the sample of 190U/L, does 1/5,2/5,3/5 respectively, 4/5 former times of dilution, records the AST-m value respectively and is 42.4U/L, 81.1U/L, 121.2U/L, 151U/L and 189.4U/L, sees Fig. 1.
As seen from the figure, AST-m is fine with lower linear at 120U/L at least, slightly is trend on the low side more than the 120U/L.
Two, reaction process curve
Figure 2 shows that the reaction process curve.The reaction process linearity is good as seen from Figure 2, illustrates that this measuring method stablizes credible.
Three, criticize interior precision
Get basic, normal, high, three serum samples respectively, differ greatly owing in fact be used as the amount of three serum samples of test, so the multiplicity of basic, normal, high each sample can't be consistent, its actual multiplicity is respectively 18,13 and 9 times, the results are shown in Table 1.
Accuracy test in the table 1 batch
| Sample | Multiplicity | Maximum | Schwellenwert | Mean value | ????CD | ????CV |
| Low | ??18 | ????8.0 | ????6.3 | ????6.9 | ????0.45 | ????6.55％ |
| In | ??13 | ????22.1 | ????20.4 | ????21.3 | ????0.52 | ????2.45％ |
| High | ??9 | ????123.1 | ????121.3 | ????122.2 | ????0.70 | ????0.57％ |
Four, criticize between precision
Get basic, normal, high three samples respectively, measure once every day, measures seven days altogether, the results are shown in Table 2.Stable by measurement result in the visible same sample of table 27 days, basic, normal, high three samples batch between CV value respectively 7.4%, 2.84% and 0.9%, even low value, the difference of mensuration maximum and high low value is 2U only, high value is 4U also, and this can not disturb diagnosis in clinical application.
Precision between table 2 batch
Measure the high value of date low value intermediate value
The 1st day 9.2 42.8 133.7
The 2nd day 9.8 43.1 130.1
The 3rd day 8.3 40.4 132.0
The 4th day 10 42.5 132.2
The 5th day 10 43.4 133
The 6th day 9.9 44.3 134
The 7th day 10.5 43.4 132
X???????????????????9.7?????????????42.8????????????132.4
SD??????????????????0.71????????????1.22????????????1.31
CV??????????????????7.4％???????????2.84％??????????0.98％
Five, reclaim experiment
Add the different reference liquids of measuring to a serum specimen, drawing the rate of recovery is 94.5%～103.7%, average 99.0%.
Six, interference test
Through the oxyphorase of test 4g/L, the bilirubin of 50 μ mol/L, the triglyceride level of 5.5 μ mol/L and 6g/L xitix do not produce interference effect to the determination of activity of m-AST, illustrate that the immunity from interference of this method is stronger.
Seven, reference value
The present invention has measured healthy people's 200 examples, and its term of reference is as follows: 6.2～17.5U/L, can assert then that as X ± 3SD 20U/L is reference upper level (a highest example is 20.5U/L in 200 routine measured values, and that minimum is 6.8U/L).
Claims (3)
1, aspartic acid based transferase Mitochondria Isoenzyme m type measuring method, it is characterized in that this method is an immunodepression, by adopting goat-anti people ASTs antibody to combine with ASTs specificity in the serum, inhibition ASTs is a non-activity, adopts the enzyme kinetics method to measure residual A STm activity in the serum then.
2, method according to claim 1 is characterized in that these method concrete steps comprise:
Get reagent I, add in the quality-control sample, put 37 ℃ of water-baths and add reagent II after 5 minutes, put 37 ℃ of water-baths after 1 minute, on spectrophotometer, measure 3 minutes absorbancy changing values with wavelength 340nm, divided by 3, calculate the absorbancy changing value Δ A/min of average per minute, press ASTm (U/L)=Δ A/min * F calculation result, wherein F is a constant-3225; Reagent I contains tris buffer, potassium aspartate, serum lactic dehydrogenase, goat-anti people ASTs antiserum(antisera), the sodium alpha-ketoglutarate of pH8.0 ± 0.2; Reagent II contains pH8.0 ± 0.2 tris buffer, sodium alpha-ketoglutarate, DPNH.
3, method according to claim 2 is characterized in that the goat-anti people ASTs antibody described in the reagent I is made by following method:
Human heart takes out in after death 24 hours, is divided into about 100g, preserves-80 ℃ of conditions and preserves stand-by;
1) the thick extraction:
Treat the tundra material, add the damping fluid that contains the pyridoxal phosphate protein stabiliser, destroy cell with the cell pulverization machine and make homogenate, the low temperature ultracentrifugation, get supernatant liquor and be heated to 50 ℃-55 ℃, the low temperature ultracentrifugation is removed the sex change foreign protein again, obtains crude extract homogenate through 50% and 33% secondary saturated ammonium sulphate, homogenate is operated under 4 ℃ of conditions with the water-soluble Jie's dialysis of distillation, concentrated;
2) chromatographic separation:
With affinity column and ion exchange column on the thick concentrated solution, collect the ASTs elutriant, by the time the ASTs antigen of purifying.Measure the purity one of purifying product then and identify that the electrophoresis position is at α with the cellulose acetate electrophoresis separation
2The sphaeroprotein position, enzyme activity determination is used clinical biology, and the biochemical method that IFCC recommends is measured the AST activity;
3) immune animal:
Get healthy, the heavily adult bright and beautiful sheep of male about 50kg, carry out immunity, add bacille Calmette-Guerin vaccine and Fu Dai adjuvant mixing with antigen for the first time, inject bright and beautiful sheep neck lymph and muscle tissue, per 2 weeks once, immunity is 4 times-5 times altogether, and the antigen amount increases and decreases according to the weight of animals, the two weeks back blood sampling that immunity is last, serum is handled purifying through 50% ammonium sulfate pay and liquid, obtain goat-anti people ASTs antiserum(antisera), mensuration is tired, and is standby.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2003101094243A CN1546683A (en) | 2003-12-15 | 2003-12-15 | Aspartic transaminase mitochondrion isozyme m type measurement method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2003101094243A CN1546683A (en) | 2003-12-15 | 2003-12-15 | Aspartic transaminase mitochondrion isozyme m type measurement method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1546683A true CN1546683A (en) | 2004-11-17 |
Family
ID=34335186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2003101094243A Pending CN1546683A (en) | 2003-12-15 | 2003-12-15 | Aspartic transaminase mitochondrion isozyme m type measurement method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1546683A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102010890B (en) * | 2009-09-08 | 2013-05-22 | 北京迪迈医学诊断技术有限公司 | Kit for determining mitochondria aspartate aminotransferase |
| CN104447998A (en) * | 2014-12-22 | 2015-03-25 | 宁波美康盛德医学检验所有限公司 | Method for preparing polyclonal antibody of human aspartic transaminase cytoplasm isozymes |
| CN104459158A (en) * | 2014-12-22 | 2015-03-25 | 宁波美康生物科技股份有限公司 | Aspartate transaminase mitochondrial isozyme detection kit |
| CN110018305A (en) * | 2019-05-12 | 2019-07-16 | 武汉生之源生物科技股份有限公司 | A kind of aspartate amino transferase Mitochondria Isoenzyme detection kit and application |
| CN110079581A (en) * | 2019-05-14 | 2019-08-02 | 天津中成佳益生物科技有限公司 | A kind of detection kit and detection method of aspartate amino transferase Mitochondria Isoenzyme |
-
2003
- 2003-12-15 CN CNA2003101094243A patent/CN1546683A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102010890B (en) * | 2009-09-08 | 2013-05-22 | 北京迪迈医学诊断技术有限公司 | Kit for determining mitochondria aspartate aminotransferase |
| CN104447998A (en) * | 2014-12-22 | 2015-03-25 | 宁波美康盛德医学检验所有限公司 | Method for preparing polyclonal antibody of human aspartic transaminase cytoplasm isozymes |
| CN104459158A (en) * | 2014-12-22 | 2015-03-25 | 宁波美康生物科技股份有限公司 | Aspartate transaminase mitochondrial isozyme detection kit |
| CN104459158B (en) * | 2014-12-22 | 2016-06-22 | 宁波美康生物科技股份有限公司 | Aspartate aminotransferase Mitochondria Isoenzyme detection kit |
| CN110018305A (en) * | 2019-05-12 | 2019-07-16 | 武汉生之源生物科技股份有限公司 | A kind of aspartate amino transferase Mitochondria Isoenzyme detection kit and application |
| CN110018305B (en) * | 2019-05-12 | 2020-12-08 | 武汉生之源生物科技股份有限公司 | Aspartate aminotransferase mitochondrial isozyme detection kit and application |
| CN110079581A (en) * | 2019-05-14 | 2019-08-02 | 天津中成佳益生物科技有限公司 | A kind of detection kit and detection method of aspartate amino transferase Mitochondria Isoenzyme |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104198473B (en) | A kind of uric acid detection kit of stabilization | |
| CN104897907B (en) | A kind of test kit detecting glycolated hemoglobin and detection method thereof | |
| CN108424952B (en) | Small and dense low-density lipoprotein cholesterol detection kit | |
| CN103320498A (en) | Detection reagent for aspartate aminotransferase | |
| CN1546683A (en) | Aspartic transaminase mitochondrion isozyme m type measurement method | |
| CN100343673C (en) | Method of measuring lipid components and method of examining renal failure | |
| CN106442355A (en) | Determination reagent for heart-type fatty acid binding protein and preparation method of determination reagent | |
| CN1094154C (en) | PCR method for testing nucleic acid by fluoremtetry and its reagent box | |
| CN109613232A (en) | A kind of detection kit and detection method of complete homogeneous determination adiponectin | |
| CN104807995B (en) | High-sensitivity continuous-detection-method GLDH (Glutamic Dehydrogenase) detection reagent | |
| CN103333945A (en) | Direct bilirubin detection reagent | |
| CN101221129B (en) | Sulfated bile acid enzyme fluorescence capillary analytical method and enzyme fluorescence quantitative reagent kit | |
| CN109342168B (en) | Triglyceride quality control liquid and preparation method thereof | |
| Warnick | Laboratory measurement of lipid and lipoprotein risk factors | |
| CN108254579B (en) | Preparation of high-density lipoprotein cholesterol detection kit with strong anti-interference capability | |
| CN1217006C (en) | Method for quantitative determination of biochemical substance by enzyme analysis via predicting background | |
| CN111024636A (en) | Colorimetric method for detecting glutathione based on CoOOH-TMB oxidation system | |
| CN1693475A (en) | Dipeptide amido peptidase TV kit | |
| Wegwerth et al. | A new test method for biochemical analysis of plasmalogens in dried blood spots and erythrocytes from patients with peroxisomal disorders | |
| Dissanayake et al. | A narrative review on laboratory investigations of serum creatinine and solutions to problems therein | |
| CN117969836B (en) | Aortic valve calcification stenosis diagnosis model constructed based on plasma inflammatory proteins and application | |
| JP2004159531A (en) | Method for assaying lysophospholipase d activity | |
| CN1428435A (en) | Liver cancer diagnosis, monitoring and liver cirthosis monitoring kit | |
| Gershbein et al. | Glycolytic enzyme levels of intraocular fluids and lens as compared to the respective sera of various animal species | |
| CN1763220A (en) | Chlorine ion content determination method and chlorine ion diagnosis kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |